Johnson & Johnson Sees $1.97M Bullish Call Sweep as Stock Hovers Near 52-Week Highs

By TrendSpider Editor

A single unusual options contract on Johnson & Johnson caught the attention of traders Thursday, with a call sweep totaling $1,974,000 in premium hitting the tape. JNJ shares are currently trading at $229.33, up 0.88% on the session, and sitting comfortably in the upper half of their 52-week range o

Johnson & Johnson Sees $1.97M Bullish Call Sweep as Stock Hovers Near 52-Week Highs

A single unusual options contract on Johnson & Johnson caught the attention of traders Thursday, with a call sweep totaling $1,974,000 in premium hitting the tape. JNJ shares are currently trading at $229.33, up 0.88% on the session, and sitting comfortably in the upper half of their 52-week range of $146.115 to $251.705. The positioning of this trade, with the strike sitting just above the current price and a short runway to expiration, suggests at least one large player is making a near-term directional bet on continued upside.

Key Drivers of the JNJ Stock Move

• Main Catalyst: One unusual call contract was flagged today on JNJ with a $230 strike expiring May 15, 2026, carrying $1,974,000 in total premium and a volume-to-open-interest ratio of 70%, signaling aggressive new positioning rather than a roll or hedge.
• Bull Case: The contract is currently in the money relative to the $230 strike given current price action near $229.33, and the 70% OI reading points to a large fresh directional bet. With just over two weeks until expiration, the buyer is wagering on a clean breakout above $230 in a compressed timeframe, consistent with conviction around a near-term catalyst.
• Bear Case: The trade is a lone contract with no supporting put activity, and the stock would need to push meaningfully above $230 before May 15 to generate a return on the $1,974,000 in premium spent. JNJ remains well below its 52-week high of $251.705, meaning the path to full upside is not without resistance, and any macro or sector-level pressure could quickly erode time value with such a tight expiration window.

Looking ahead, the May 15 expiration date gives this trade a very short leash. The $230 level represents a key line in the sand for JNJ bulls, and a sustained move above it could open the door toward the mid-$230s and beyond. Johnson & Johnson has been navigating a complex operating environment that includes ongoing litigation matters related to its talc liability settlements, as well as continued progress integrating its MedTech and Innovative Medicine segments following the Kenvue spin-off. Any earnings revisions, pipeline updates, or litigation developments in the next two weeks could act as the catalyst this options buyer appears to be anticipating. With zero put contracts flagged alongside this call sweep, the options flow carries a distinctly one-sided, bullish tone heading into May.

JNJ Unusual Options Activity

One unusual contract was flagged in Thursday's session:

• Type: Call | Strike: $230 | Expiry: May 15, 2026 | Volume: 4,200 | Open Interest: 70% OI ratio

Total premium on the flagged activity came in at $1,974,000 across one contract summary. There were no unusual put contracts reported in the same session, leaving the unusual flow entirely skewed to the call side.

JNJ Seasonality

Late April and early May have historically been an active period for JNJ given the company's tendency to report quarterly earnings in that window, which can amplify options activity and short-term volatility around key price levels. The short-dated nature of this May 15 contract aligns with that seasonally event-driven pattern.

JNJ Relative Performance

JNJ is currently trading at $229.33, representing a substantial recovery from its 52-week low of $146.115, and sitting within roughly $22 of its 52-week high of $251.705. The 0.88% gain on the session puts JNJ in positive territory on the day, outperforming many of its large-cap healthcare peers that have faced pressure from ongoing policy uncertainty around drug pricing. The stock's positioning in the upper quartile of its annual range reflects relative strength within the healthcare sector.